99 related articles for article (PubMed ID: 7769797)
1. Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans.
MacFadyen RJ; Jones CR; Doig JK; Birnbock H; Reid JL
J Cardiovasc Pharmacol; 1995 Mar; 25(3):347-53. PubMed ID: 7769797
[TBL] [Abstract][Full Text] [Related]
2. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers.
Doig JK; MacFadyen RJ; Sweet CS; Reid JL
J Cardiovasc Pharmacol; 1995 Apr; 25(4):511-7. PubMed ID: 7596116
[TBL] [Abstract][Full Text] [Related]
3. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man.
Doig JK; MacFadyen RJ; Sweet CS; Lees KR; Reid JL
J Cardiovasc Pharmacol; 1993 May; 21(5):732-8. PubMed ID: 7685442
[TBL] [Abstract][Full Text] [Related]
4. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
5. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
[TBL] [Abstract][Full Text] [Related]
7. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
[TBL] [Abstract][Full Text] [Related]
9. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
Himmelmann A; Bergbrant A; Svensson A; Hansson L; Aurell M
Am J Hypertens; 1996 Jun; 9(6):517-22. PubMed ID: 8783774
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
11. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
Burnier M; Rutschmann B; Nussberger J; Versaggi J; Shahinfar S; Waeber B; Brunner HR
Hypertension; 1993 Sep; 22(3):339-47. PubMed ID: 8349327
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
13. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.
Opsahl JA; Goldberg MR; Katz SA
Am J Hypertens; 1995 Nov; 8(11):1090-8. PubMed ID: 8554732
[TBL] [Abstract][Full Text] [Related]
14. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
[TBL] [Abstract][Full Text] [Related]
15. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM
J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
[TBL] [Abstract][Full Text] [Related]
16. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
[TBL] [Abstract][Full Text] [Related]
17. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension.
van Paassen P; de Zeeuw D; de Jong PE
J Cardiovasc Pharmacol; 1995 Jul; 26(1):39-45. PubMed ID: 7564363
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
[TBL] [Abstract][Full Text] [Related]
19. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
Munafo A; Christen Y; Nussberger J; Shum LY; Borland RM; Lee RJ; Waeber B; Biollaz J; Brunner HR
Clin Pharmacol Ther; 1992 May; 51(5):513-21. PubMed ID: 1587065
[TBL] [Abstract][Full Text] [Related]
20. Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men.
Doig JK; MacFadyen RJ; Meredith PA; Fischli W; Reid JL
J Cardiovasc Pharmacol; 1992 Dec; 20(6):875-80. PubMed ID: 1282588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
